Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Wearable Diagnostic for Detection of COVID-19 Infection

18. januar 2022 opdateret af: ClinOne, Inc.
The goals of this study are 1) to validate the use of a wearable diagnostic capability and software as a medical device (SaMD) algorithm for the pre or early-symptomatic detection of COVID-19 infection, 2) assess the wearable device on the subjects, and 3) ensure data are collected, securely stored, and easily read and interpreted by non-laboratory personnel.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

This is an open label iterative study designed to calibrate the algorithm to maximize its test characteristics. The sample size is derived from the minimum number of COVID-19 subjects required to evaluate algorithm sensitivity and specificity. A sample size of 200 true positive COVID-19 infections is anticipated to assess device predictive analytics. Assuming a six-month enrollment period, a 15 percent patient lost to follow-up rate, and a positive COVID-19 infection rate of 10 percent within the study population, a sample size of 2,352 subjects will be enrolled in this prospective study.

Primary Outcomes: The primary outcomes of interest are performance of the BioSticker multiparameter vital signs wearable and the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19 related signs and symptom in subjects prior to or coincident with a positive COVID-19 diagnostic test and the specificity of the BioSticker algorithms in distinguishing positive diagnosis of infection from negative diagnosis of infection among subjects. COVID-19 infection will be confirmed by both participant affirmation and diagnostic laboratory testing. Additional primary outcome is the intuitive presentation of affirmative diagnostic results from the BioSticker early detection algorithm(s).

Secondary Outcomes: The secondary outcomes of interest include correlation of biometric data indicators to individual-level experiential feedback reported through participant symptom-tracking and diagnostic questionnaires.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

790

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Colorado
      • Greenwood Village, Colorado, Forenede Stater, 80111
        • ClinOne, Inc

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

Cohort 1- Exposed/Early Symptomatic Group All adult subjects seeking a COVID-19 test and meeting enrollment criteria will be offered enrollment into this study.

The Inclusion Criteria are:

  1. Adults - 18 years of age and older
  2. Both genders, all races and ethnic groups
  3. English speaking adult subjects only

Cohort 2- Vaccine Group:

Potential subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine

  1. Subjects who are scheduled to receive the COVID vaccination series through local and national clinics, health systems and pharmacies.
  2. Subjects who become aware of the study through public notices, postings, and advertisements, and other marketing efforts.

Beskrivelse

Cohort 1- Exposed/ Early Symptomatic Group

Inclusion Criteria:

  1. age 18 or older;
  2. able to follow the study device wear instructions per the Instructions for Use;
  3. no positive viral test within 60 days prior to enrollment; and
  4. willing and able to provide written, informed consent.

Exclusion Criteria:

  1. pregnant or breastfeeding;
  2. wearing a defibrillator or pacemaker;
  3. known or suspected cardiac dysrhythmias
  4. known or suspected allergy to adhesives;
  5. chronic daily use of non-steroidal anti-inflammatory medications (NSAIDs) and antipyretic medications
  6. open wounds or infected, irritated, scarred, or inflamed areas of skin on the upper chest preventing placement of the biosensor; and
  7. current or planned use of either an investigation pharmaceutical or an investigational device during the study.

Cohort 1- Vaccine Group

Inclusion Criteria:

Subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series are eligible for the study if they are:

  1. Age 18 or older; 12 years of age -17 years of age are approved to participate in the vaccine Cohort portion of the study.
  2. scheduled to receive their first and second dose of the Pfizer/BioNTech or Moderna COVID-19 vaccine
  3. able to follow the study device wear instructions per the Instructions for Use;
  4. no positive viral test within 60 days prior to enrollment; and
  5. willing and able to provide written, informed consent.
  6. Willing and able to take an oral temperature

Exclusion Criteria:

Potential subjects seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series will be excluded from the study if they are or have any of the following:

  1. pregnant or breastfeeding;
  2. wearing a defibrillator or pacemaker;
  3. known or suspected cardiac dysrhythmias
  4. known or suspected allergy to adhesives;
  5. chronic daily use of non-steroidal anti-inflammatory medications (NSAIDs) and antipyretic medications
  6. open wounds or infected, irritated, scarred, or inflamed areas of skin on the upper chest preventing placement of the biosensor; and
  7. current or planned use of either an investigation pharmaceutical or an investigational device during the study.
  8. previously fully vaccinated subjects

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Cohort 1- Exposed/Early Symptomatic

The population identified for this study includes subjects who request COVID-19 testing in response to a concern for recent COVID-19 exposure and/or concern of COVID-19-like related symptoms. We will recruit and enroll patients through public facing websites, clinic and pharmacy vaccination schedules and on-site vaccination marketing.

For the population with recent COVID-19 exposure and/or concern of COVID-19-like related symptoms, population identification includes subjects who visit eTrueNorth's https://www.doineedacovid19test.com/ website where subjects have access to over 7,500 testing site locations across the nation. Otherwise, individuals seeking COVID-19 testing will be directed to the ClinOne, Inc. website for information regarding the Wearable Diagnostic for Detection of COVID-19 Infection study contact information for study participation, enrollment into the study using eConsent, and will receive a BioSticker wearable kit by express mail the next day.

CoHort 2- Pfizer or Moderna Vaccine
Secondly, the other population identified for this study includes subjects who are scheduled for the first and second dose of the mRNA-based Pfizer/BioNTech and Moderna vaccine series. For the population seeking the mRNA-based Pfizer/BioNTech and Moderna vaccine series, we will recruit and enroll patients through public-facing websites, clinic, and pharmacy vaccination schedules, and on-site vaccination marketing

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor.
Tidsramme: 14 days
Biometric data will be measured for 14 days using the application of the BioSticker on the upper left side of the chest.
14 days
The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor.
Tidsramme: 14 days
Vital Signs measurements will be collected for 14 days using the application of the BioSticker on the upper left side of the chest.
14 days
The primary outcome of interest are performance of the BioSticker wearable for detecting early onset of active COVID-19 related symptoms.
Tidsramme: 14 days
Symptom tracking data will be collected through daily questionnaires for 14 consecutive days, administered through ClinOne. Health data known to be associated with COVID-19 risk and severity, including comorbid conditions, risk factors, and demographic data will be collected from subjects during screening and enrollment via the ClinOne study website.
14 days
The primary outcome of interest is the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19.
Tidsramme: 14 days
BioSticker sensor data will be time-stamped and annotated against clinical events (e.g., fever, cough), symptom progression data, and other indicators of infection as they are identified. Weighting coefficients for predictive algorithms will be tuned and algorithms will be iteratively refined using machine learning methods and small batches of data anticipated to include between 20 and 50 positive cases per set, and validated against sensor data obtained from COVID-19-negative subjects.
14 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The secondary outcomes of interest include correlation of biometric data indicators to patient reported symptoms.
Tidsramme: 14 days
Individual-level experiential feedback will be reported through participant symptom- tracking and diagnostic questionnaires for 14 consecutive days.
14 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: James Mault, MD, BioIntelliSense, Inc

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. december 2020

Primær færdiggørelse (Faktiske)

15. januar 2022

Studieafslutning (Faktiske)

15. januar 2022

Datoer for studieregistrering

Først indsendt

14. januar 2021

Først indsendt, der opfyldte QC-kriterier

5. februar 2021

Først opslået (Faktiske)

8. februar 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. januar 2022

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. januar 2022

Sidst verificeret

1. januar 2022

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med COVID-19

3
Abonner